European Heart Journal

Papers
(The TQCC of European Heart Journal is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure4978
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)4742
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2627
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2239
2021 ESC/EACTS Guidelines for the management of valvular heart disease1870
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension857
2020 ESC Guidelines for the management of adult congenital heart disease852
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy793
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease735
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus 722
COVID-19 is, in the end, an endothelial disease649
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era640
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death612
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio608
Coronaviruses and the cardiovascular system: acute and long-term implications503
Acute pulmonary embolism and COVID-19 pneumonia: a random association?463
Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage430
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe404
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin397
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy396
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases392
Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection367
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors360
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula355
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019344
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study335
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis310
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research306
European Society of Cardiology: cardiovascular disease statistics 2021302
The ‘Digital Twin’ to enable the vision of precision cardiology297
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?289
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study279
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather271
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus265
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force259
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance256
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery253
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement249
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation243
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial242
COVID-19-related myocarditis in a 21-year-old female patient238
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine231
C-reactive protein and clinical outcomes in patients with COVID-19229
Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts221
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis200
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement194
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study191
2023 ESC Guidelines for the management of acute coronary syndromes185
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions182
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests176
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes175
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc173
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study173
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease169
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o168
Targeting cardiovascular inflammation: next steps in clinical translation162
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy162
Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19159
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)156
Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial149
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement146
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials144
Left bundle branch area pacing outcomes: the multicentre European MELOS study144
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)140
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry139
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)136
Typical takotsubo syndrome triggered by SARS-CoV-2 infection136
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk134
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction132
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial132
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes132
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy129
Prevalence of statin intolerance: a meta-analysis128
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study126
Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation123
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists123
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults121
Heart failure drug treatment: the fantastic four119
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020118
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies116
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial115
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study115
European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (112
Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials111
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials110
Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair110
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial109
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)108
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure107
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes107
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial107
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank107
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF107
2023 ESC Guidelines for the management of cardiomyopathies106
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme105
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank105
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies104
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery104
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction103
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial103
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial102
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis102
Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study99
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism96
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake96
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic96
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study94
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk93
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial92
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves91
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study91
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation90
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up90
Vulnerable plaques and patients: state-of-the-art89
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry88
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial88
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS88
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of ran87
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk87
Application of artificial intelligence to the electrocardiogram86
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)85
Combination lipid-lowering therapy as first-line strategy in very high-risk patients84
Empagliflozin in acute myocardial infarction: the EMMY trial84
Electrocardiogram screening for aortic valve stenosis using artificial intelligence84
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome82
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people82
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s81
Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype81
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world80
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis80
Genetic predisposition to smoking in relation to 14 cardiovascular diseases79
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study79
Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years78
Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy78
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations78
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis78
Colchicine and the heart77
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial77
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group77
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry77
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation77
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)77
High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population76
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes76
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta75
Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis75
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA74
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial74
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry74
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction73
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th73
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease73
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials72
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial72
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial72
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial72
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study71
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study71
Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies71
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo70
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial70
Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammatio69
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy69
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial69
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study69
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications69
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction69
Return to sports after COVID-19 infection68
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease68
2023 ESC Guidelines for the management of endocarditis68
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance68
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial67
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study67
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk67
A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE266
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study66
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study66
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis66
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial66
Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study65
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure65
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat65
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction65
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study64
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study64
The win ratio approach for composite endpoints: practical guidance based on previous experience64
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction64
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the E64
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis64
Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study64
Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak64
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy63
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials63
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis62
Feasibility of using deep learning to detect coronary artery disease based on facial photo61
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial61
Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study61
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole61
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He61
Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)61
COVID-19: from epidemiology to treatment61
Transient complete heart block in a patient with critical COVID-1960
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences60
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis60
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data60
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy60
Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention60
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality60
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection60
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study60
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms59
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models59
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality59
Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement59
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up58
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme58
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology 58
The associations of major foods and fibre with risks of ischaemic and haemorrhagic stroke: a prospective study of 418 329 participants in the EPIC cohort across nine European countries58
Road traffic noise and cardiovascular disease risk factors in UK Biobank58
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study57
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial57
Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-1957
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases57
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases56
Brugada syndrome genetics is associated with phenotype severity56
Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective56
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation56
TeleCheck-AF for COVID-1956
Does epicardial fat contribute to COVID-19 myocardial inflammation?55
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis55
Assessing left ventricular systolic function: from ejection fraction to strain analysis55
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy55
Effects of canagliflozin on human myocardial redox signalling: clinical implications54
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study54
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial54
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs54
Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease54
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey54
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study53
Targeting the CCL2–CCR2 axis for atheroprotection53
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease53
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?53
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data53
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score53
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome52
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s52
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR52
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial52
The struggle towards a Universal Definition of Heart Failure—how to proceed?52
Clinical application of the 4th Universal Definition of Myocardial Infarction52
0.066634893417358